“We began laying the groundwork for entrance into this important, thriving market upon participating in the 14th Annual Meeting of the Taiwan Neurosurgical Society in 2019, and we are pleased to see these efforts coming to fruition,” said Daniel Chon, CTL Amedica Corporation president and CEO. “The Valeo product line features our proprietary silicon nitride spine technology, the ideal biomaterial for fusion.”
CTL Amedica is the world’s exclusive provider of silicon nitride spine products. Silicon nitride demonstrates unique bacteriostatic properties, provides superior imaging across all modalities and promotes an enhanced osteogenic response.
“We are very excited to put CTL Taiwan in motion and look forward to working with our Taiwan distributor partner, Watson Biomedical Technology of New Taipei City, to make this unparalleled technology readily available throughout the country and eventually in markets throughout Asia,” Chon said.
The Valeo product line is projected to commercialize later this year in Taiwan.